Mannkind Corporation (MNKD) - News Archive

MannKind Corporation Expands Leadership and Records Impressive Revenue Growth Danbury, Conn. and Westlake Village, Calif. – On January 6, 2025, MannKind Corporation (Nasdaq: MNKD), a pioneer in the development of innova...

MannKind Corporation has recently made significant strides in the field of inhaled therapies, garnering attention with the announcement of encouraging six-month results from its Phase 3 trial investigating inhaled insul...

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases MannKind Corporation has announced a significant milestone with the successful completion of a Phase 1 clinical...

Breakthrough Study Reveals Positive Impact of Inhaled Insulin on A1C Goals for Adults with Type 1 DiabetesRecent findings from a pivotal study have unveiled encouraging results regarding the management of Type 1 diabete...

News MannKind Corporation (NASDAQ: MNKD) has announced that it has received clearance from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate a Phase 3 clinical trial, known as ICoN-1, evaluating...

CSIMarket.com is pleased to present an analysis of the recently concluded INHALE-3 study, which compared the efficacy of inhaled insulin with usual care in the treatment of Type 1 Diabetes (T1D). Additionally, we will d...

Diabetes mellitus, a chronic condition characterized by hyperglycemia, necessitates continuous innovation in treatment modalities to optimize glycemic control and improve patient quality of life. Traditional subcutaneou...

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction with Pulmatrix Valencia, Calif., October XX, 2023 - MannKind Corporation, a compa...

MannKind, a leading biopharmaceutical company, is making significant strides in the treatment of pulmonary fibrotic diseases and pediatric diabetes. The company recently announced its plans to proceed with a Phase 1 stu...

MannKind Corporation recently made significant strides in advancing the treatment landscape for Nontuberculous Mycobacterial (NTM) lung disease, as they received the Investigational New Drug (IND) clearance from the US...

In a recent press release, MannKind Corporation proudly announced that it has successfully repaid all outstanding indebtedness under its credit and security agreement with MidCap Financial Trust, as well as its converti...

INHALE-3 Study s Initial Meal Challenge Results Comparing Afrezza Head-to-Head with Multiple Daily Injections (MDI) and Insulin PumpsRecently, the INHALE-3 study released its initial meal challenge results, which compar...

for MannKind Corporation, a renowned pharmaceutical company, has recently announced the successful completion of the enrollment goal for their INHALE-1 Pediatric Diabetes Trial involving the utilization of Afrezza. This...